Lidoderm Antitrust

SAN FRANCISCO – A drug maker that dropped its patent suit against makers of the pain patch Lidoderm and agreed to delay its generic version could have won its lawsuit, an “alternate injury in a but-for world” that precludes resolving a sprawling antitrust class action in the drug makers’ favor, a federal judge has ruled.

%d bloggers like this: